1st Quarter - Report
THE UNITED STATES PHARMACOPEIAL CONVENTION for THE UNITED STATES PHARMACOPEIAL CONVENTION
Income
—
Expenses
$110,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S.2315, Over-the-Counter Drug Safety, Innovation, and Reform Act; Over-the-counter reform; Role of USP monographs in FDAs OTC monograph system; FDA appropriations; role of quality standards; The role of USP standards in compounding law; USP work on opioids; role of USP standards to facilitate access to generic drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARRIE HARNEY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.